article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.

article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

However, patient uptake hasn’t matched rising market competition. Among surveyed patients, nearly half (47%) couldn’t remember a single preventive migraine brand name, and the leading brand patients did recall— Topamax —is an older drug that was approved for migraine in 2004.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.

article thumbnail

Uri Goren

Cadensee

When he was going through his cancer, he died in 2004. Giving them input and sharing stuff that happens outside the Ministry of Health view, and tries to help them on strategic decisions on process, on gauging out what would the industry think, what would the healthcare providers think.